Suspended

Assessment of Ganciclovir Response in CMV Infection Using Quantitative Real-Time PCR

Study Aim

This study aims to assess how well individuals with CMV infection respond to Ganciclovir treatment, using Quantitative Real-Time PCR as a diagnostic tool.

What is being tested

ganciclovir

Drug

Who is being recruted

DNA Virus Infections+2

+ Herpesviridae Infections

+ Infections

Over 18 Years

+10 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Diagnostic Study

Interventional

See protocol details

Summary

Principal SponsorNational Center for Research Resources (NCRR)

Last updated: June 24, 2005

Sourced from a government-validated database.Claim as a partner

This research aims to create and utilize a blood test to understand how swiftly the drug ganciclovir acts against the CMV virus (Cytomegalovirus). The test could potentially alert doctors early in the treatment if the virus is not responding well, indicating possible resistance to the drug. The study focuses mainly on kidney and lung transplant patients who have CMV detected in their blood, but other patients may also participate if they fit the criteria.

NCT00004573

Principal SponsorNational Center for Research Resources (NCRR)

Last updated: June 24, 2005

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

DNA Virus InfectionsHerpesviridae InfectionsInfectionsVirus DiseasesCytomegalovirus Infections

Criteria

4 inclusion criteria required to participate

All patients will have a positive qualitative CMV PCR or viral culture before starting therapy

It is anticipated that most subjects will be organ transplant recipients but this is not a requirement of the study

Patients affiliated with Barnes-Jewish Hospital with CMV blood infection requiring antiviral therapy

Patients will receive treatment with ganciclovir at a dose and duration to be determined by the provider

6 exclusion criteria prevent from participating

Anemia (HGB < 8 g/dl) that would contraindicate the extra blood draws required by this study

Critically ill patients

Patients who are unable to provide informed consent because of diminished capacity related to illness, dementia, or other reasons

Patients with profound leukopenia or abnormal renal function that make a change in the antiviral drug dosage likely during the duration of the study

Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Infectious Diseases Division

St Louis, United StatesOpen Infectious Diseases Division in Google Maps

SuspendedOne Study Center